Novo Holdings is reportedly set to receive unconditional EU antitrust approval for its acquisition of drug maker Catalent, valued at $16.5 billion. This development follows a series of significant transactions in the pharmaceutical sector. Novartis has announced the acquisition of Kate Therapeutics for up to $1.1 billion, enhancing its capabilities in neuroscience drug development and gene therapy. Additionally, Ratio Therapeutics has entered into an exclusive worldwide agreement with Novartis, potentially worth $745 million, for the development of a radiotherapeutic candidate aimed at cancer treatment. Furthermore, Novartis has signed a research collaboration and license agreement with Schrödinger, potentially exceeding $2 billion, to advance multiple small molecule candidates into its portfolio.